1. |
Michalski CW, Weitz J, Büchler MW. Surgery insight: surgical management of pancreatic cancer [J]. Nat Clin Pract Oncol, 2007, 4(9): 526535.
|
2. |
Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic selftolenrance maintained by actived T cells expressing Il2 receptor αchain (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune disease [J]. J Immunol, 1995, 155(3): 11511164.
|
3. |
Abdulamir AS, Kadhim HS, Hafidh RR, et al. Severity of asthma: the role of CD25+, CD30+, NFκB, and apoptotic markers [J]. J Investig Allergol Clin Immunol, 2009, 19(3): 218224.
|
4. |
Stephens LA, Malpass KH, Anderton SM, et al. Curing CNS autoimmune disease with myelinreactive Foxp3+ Treg [J]. Eur J Immunol, 2009, 39(4): 11081117.
|
5. |
Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4+CD25+ T cells in tumors from patients with earlystage nonsmall cell lung cancer and latestage ovarian cancer [J]. Cancer Res, 2001, 61(12): 47664772.
|
6. |
Sasada T, Kimura M, Yoshida Y, et al. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies:possible involvement of regulatory T cells in dieases progression [J]. Cancer, 2003, 98(5): 10891099.
|
7. |
Omandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocelluar carcinoma [J]. Cancer Res, 2005, 65(6): 24572464.
|
8. |
刘俊田, 岳杰, 任秀宝, 等. 乳腺癌患者外周血CD4+CD25+调节性T细胞的检测及意义 [J]. 中华肿瘤杂志, 2005, 27(7): 423425.
|
9. |
Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma [J]. J Immunol, 2002, 169(5): 27562761.
|
10. |
Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions [J]. Clin Cancer Res, 2006, 12(18): 54235434.
|
11. |
Kono K, Kawaida H, Takahashi A, et al. CD4+CD25high regulatory T cells increase with tumor stage in patient with gastric and esophageal cancers [J]. Cancer Immunol Immunother, 2006, 55(9): 10641071.
|
12. |
Peng L, Kiaergard J, Plautz GE, et al. Tumorinduced Lselectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy [J]. J Immunol, 2002, 169(9): 48114821.
|
13. |
邬玉辉, 申正堂, 海健, 等. 乳腺癌患者细胞免疫功能的检测 [J]. 中国医师杂志, 2001, 3(8): 627628.
|
14. |
Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase2/prostaglandin E2dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer [J]. Cancer Res, 2005, 65(12): 52115220.
|
15. |
Valzasina B, Piconese S, Guiducci C, et al. Tumorinduced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent [J]. Cancer Res, 2006, 66(8): 44884495.
|
16. |
Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells conver immature myeloid dendritic cells into TGFβsecreting cells inducing CD4+CD25+ regulatory T cell proliferation [J]. J Exp Med, 2005, 202(7): 919929.
|
17. |
MooYoung TA, Larson JW, Belt BA, et al. Tumorderived TGFβ mediates conversion of CD4+Foxp3+ regulatory T Cells in a murine model of pancreas cancer [J]. J Immunother, 2009, 32(1): 1221.
|
18. |
Curiel J, Conkos G, Zou L, et al. Specifc recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med, 2004,10(9): 942949.
|
19. |
Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells [J]. J Clin Invest, 2005, 115(12): 36233633.
|
20. |
Nummer D, SuriPayer E, SchmitzWinnenthal H, et al. Role of tumor endothelium in CD4+CD25+ regulatory T cell infiltration of human pancreatic carcinoma [J]. J Natl Cancer Inst, 2007, 99(15): 11881199.
|